361 related articles for article (PubMed ID: 28332704)
21. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
[TBL] [Abstract][Full Text] [Related]
22. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan.
Chen W; Wu CS; Liu CC; Kuo PH; Chan HY; Lin YH; Chung YE; Chen WJ
JAMA Netw Open; 2024 Jun; 7(6):e2417006. PubMed ID: 38884998
[TBL] [Abstract][Full Text] [Related]
23. Second-generation antipsychotic long-acting injections in bipolar disorder: Systematic review and meta-analysis.
Prajapati AR; Wilson J; Song F; Maidment I
Bipolar Disord; 2018 Dec; 20(8):687-696. PubMed ID: 30417552
[TBL] [Abstract][Full Text] [Related]
24. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.
Kishimoto T; Hagi K; Nitta M; Leucht S; Olfson M; Kane JM; Correll CU
Schizophr Bull; 2018 Apr; 44(3):603-619. PubMed ID: 29868849
[TBL] [Abstract][Full Text] [Related]
26. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
27. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis.
Lian L; Kim DD; Procyshyn RM; Fredrikson DH; Cázares D; Honer WG; Barr AM
Early Interv Psychiatry; 2022 Jun; 16(6):589-599. PubMed ID: 34263540
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
29. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study.
Miura G; Misawa F; Kawade Y; Fujii Y; Mimura M; Kishimoto T
J Clin Psychopharmacol; 2019; 39(5):441-445. PubMed ID: 31415288
[TBL] [Abstract][Full Text] [Related]
30. [A history of antipsychotic long-acting injections in the treatment of schizophrenia].
Crocq MA
Encephale; 2015 Feb; 41(1):84-92. PubMed ID: 25598520
[TBL] [Abstract][Full Text] [Related]
31. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.
MacEwan JP; Kamat SA; Duffy RA; Seabury S; Chou JW; Legacy SN; Hartry A; Eramo A; Karson C
Psychiatr Serv; 2016 Nov; 67(11):1183-1188. PubMed ID: 27417897
[TBL] [Abstract][Full Text] [Related]
32. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
Fang SC; Huang CY; Shao YJ
J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
[No Abstract] [Full Text] [Related]
33. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
[TBL] [Abstract][Full Text] [Related]
34. Community treatment orders and antipsychotic long-acting injections.
Lambert TJ; Singh BS; Patel MX
Br J Psychiatry Suppl; 2009 Nov; 52():S57-62. PubMed ID: 19880919
[TBL] [Abstract][Full Text] [Related]
35. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
[TBL] [Abstract][Full Text] [Related]
36. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
Gentile S
Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
[TBL] [Abstract][Full Text] [Related]
37. Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics.
Lin CH; Chan HY; Wang FC; Hsu CC
Ther Adv Psychopharmacol; 2022; 12():20451253221079165. PubMed ID: 35340566
[TBL] [Abstract][Full Text] [Related]
38. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.
Suzuki T
Expert Opin Drug Deliv; 2016; 13(2):253-64. PubMed ID: 26636244
[TBL] [Abstract][Full Text] [Related]
39. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
Graffino M; Montemagni C; Mingrone C; Rocca P
Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.
Ostuzzi G; Mazzi MA; Terlizzi S; Bertolini F; Aguglia A; Bartoli F; Bortolaso P; Callegari C; Caroleo M; Carrà G; Corbo M; D'Agostino A; Gastaldon C; Lucii C; Magliocco F; Martinotti G; Nosé M; Ostinelli EG; Papola D; Piccinelli MP; Piccoli A; Purgato M; Tabacchi T; Turrini G; Ruggeri M; Barbui C;
PLoS One; 2018; 13(8):e0201371. PubMed ID: 30071042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]